Charnwood Discovery and Intelligent Omics Announce Strategic Collaboration

Charnwood Discovery LaboratoryCharnwood Discovery a leading drug discovery research partner has announced a strategic collaboration with Intelligent OMICS Ltd (Intellomx) who specialise in applying artificial intelligence (AI) and Machine Learning (ML) to accelerate drug discovery.

The collaboration will enable Charnwood Discovery to enhance its already extensive drug discovery services through Intellomx’s AI platform which enables the identification of previously unattainable targets.

Dr Francesca Sadler, Charnwood Discovery’s Chief Commercial Officer commented:

“This exciting collaboration with Intellomx will help us to further enhance our global clients’ experience and success of drug discovery. Their innovative use of AI and ML to gain a deeper understanding of diseases perfectly complements our own services from standalone through to fully integrated drug discovery. “

Dr Robert Grundy, CEO of Intelligent OMICS adds:

“I’m certain that this collaboration with Charnwood Discovery will enable us to showcase our revolutionary technology to a wider audience and help them accelerate their discovery programs.

By delving deep into transcriptomic, genomic and proteomic data sets, novel biological targets are uncovered and existing pathways validated, paving the way for groundbreaking treatments.”

To find out more about this collaboration and how it may enhance your drug discovery program please contact us here www.charnwooddiscovery.com/contact-us